Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148663 | 1.00 | CDK5 (0.32) | CDK5CDK5R1SIGMAR1CCNA2CDK2 | |
| SCHEMBL159386 | 0.98 | CDK5 (0.33) | CDK5CDK5R1SIGMAR1CCNA2CDK2 | |
| SCHEMBL558013 | 0.93 | — | — | |
| SCHEMBL557652 | 0.74 | PLK1 (0.41) | GRM5 | |
| SCHEMBL1593106 | 0.69 | HTR2C (0.41) | — | |
| SCHEMBL190720 | 0.69 | POLB (0.39) | — | |
| SCHEMBL4141897 | 0.65 | OR51E2 (0.32) | — | |
| SCHEMBL22694432 | 0.65 | — | — | |
| SCHEMBL3341697 | 0.65 | NNMT (0.38) | — | |
| SCHEMBL910531 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050970-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2017-02-23 | — | — | US | claimed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | claimed |
| WO-2024151489-A1 | PHARMACEUTICAL PYRIDYL COMPOSITIONS AND METHODS FOR USE | Unicycive Therapeutics Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-12036078-B2 | Oral products and methods for producing the same | PolySpectra, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036211-B2 | Nicorandil derivatives | Unicycive Therapeutics Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024148191-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2009002984-A2 | STABLE AND COMPATIBLE POLYMER BLENDS | AEGIS BIOSCIENCES LLP (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080316678-A1 | Nanoparticle ultracapacitor | DAIS ANALYTIC CORPORATION | 2008-12-25 | — | — | US | disclosed |
| WO-2008141179-A1 | MOLECULE SULFONATION PROCESS | AEGIS BIOSCIENCES LLP (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080227789-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008089484-A1 | MULTI-PHASE SELECTIVE MASS TRANSFER THROUGH A MEMBRANE | DAIS ANALYTIC CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008080134-A2 | 4-AMIN0-2- (HETERO) ARYLAMINO-5- (HETERO) ARYLTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008039779-A2 | ENHANCED HVAC SYSTEM AND METHOD | DAIS ANALYTIC CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CDK5 310/4885CDK5R1 313/4885SIGMAR1 4555/4885 |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CDK5 1029/4885CDK5R1 1325/4885SIGMAR1 3515/4885 |
| US-20170050970-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | CDK5 260/4885CDK5R1 554/4885SIGMAR1 4702/4885 |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | PSMG3, PSMD1, PSMD3 | CDK5 723/4885CDK5R1 818/4885SIGMAR1 3200/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | CDK5 1284/4885CDK5R1 2059/4885SIGMAR1 4804/4885 |
| US-12036211-B2 | Nicorandil derivatives | NAPRT, NQO1, NME4 | CDK5 452/4885CDK5R1 435/4885SIGMAR1 2279/4885 |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CDK5 127/4885CDK5R1 364/4885SIGMAR1 3383/4885 |
| US-20080227789-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | CDK5 194/4885CDK5R1 158/4885SIGMAR1 2675/4885 |
| US-12036078-B2 | Oral products and methods for producing the same | CROCC, RPAP1, RUVBL1 | CDK5 583/4885CDK5R1 373/4885SIGMAR1 4324/4885 |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | AXL, FLT3, FLT1 | CDK5 92/4885CDK5R1 102/4885SIGMAR1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.